Victoria Atkinson

19.2k total citations · 3 hit papers
122 papers, 5.1k citations indexed

About

Victoria Atkinson is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Victoria Atkinson has authored 122 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 65 papers in Molecular Biology and 23 papers in Immunology. Recurrent topics in Victoria Atkinson's work include Cancer Immunotherapy and Biomarkers (66 papers), Melanoma and MAPK Pathways (63 papers) and CAR-T cell therapy research (47 papers). Victoria Atkinson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (66 papers), Melanoma and MAPK Pathways (63 papers) and CAR-T cell therapy research (47 papers). Victoria Atkinson collaborates with scholars based in Australia, United States and Italy. Victoria Atkinson's co-authors include Georgina V. Long, Grant A. McArthur, Antoni Ribas, Alexander M. Menzies, Paolo A. Ascierto, James Larkin, Alexander Guminski, Shahneen Sandhu, Mario Mandalà and Caroline Dutriaux and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Victoria Atkinson

118 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 1.5k citations James Larkin, Paolo A. Ascierto et al. profile →
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

2018 655 citations Georgina V. Long, Victoria Atkinson et al. profile →
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Alexander M. Menzies, Douglas B. Johnson et al. Annals of Oncology profile →

Peers

Victoria Atkinson

ONCOL

IMMUN

PRM

GENET

Caroline Dutriaux France

Pier Francesco Ferrucci Italy

Michael Millward Australia

Agop Y. Bedikian United States

Lia Gore United States

Nageatte Ibrahim United States

Pippa Corrie United Kingdom

Ahmad A. Tarhini United States

Jacob Schachter Israel

Lawrence E. Flaherty United States

Caroline Dutriaux France

Victoria Atkinson

3.0k ×0.8

ONCOL

3.0k ×1.2

611 ×0.6

IMMUN

450 ×0.4

PRM

211 ×0.5

GENET

Citations per year, relative to Victoria Atkinson Victoria Atkinson (= 1×) peers Caroline Dutriaux

Countries citing papers authored by Victoria Atkinson

Since Specialization

Citations

This map shows the geographic impact of Victoria Atkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Atkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Atkinson more than expected).

Fields of papers citing papers by Victoria Atkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Atkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Atkinson. The network helps show where Victoria Atkinson may publish in the future.

Co-authorship network of co-authors of Victoria Atkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Atkinson. A scholar is included among the top collaborators of Victoria Atkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Atkinson. Victoria Atkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hauschild, Axel, Reinhard Dummer, Mario Santinami, et al.. (2024). Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.. Journal of Clinical Oncology. 42(16_suppl). 9500–9500. 2 indexed citations

Saw, Robyn P.M., Kerry A. Sherman, Victoria Atkinson, et al.. (2023). Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey. Quality of Life Research. 32(12). 3531–3545. 1 indexed citations

Aoude, Lauren G., Sandra Brosda, Jessica Ng, et al.. (2023). Circulating Tumor DNA. Journal of Molecular Diagnostics. 25(10). 771–781. 9 indexed citations

Weber, Jeffrey S., Adnan Khattak, Matteo S. Carlino, et al.. (2023). LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. Annals of Oncology. 34. S1288–S1289. 5 indexed citations

Shanker, Mihir, Victoria Atkinson, Wen Xu, et al.. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology. 66(4). 536–545. 8 indexed citations

Homicskó, Krisztián, Reinhard Dummer, Christoph Höeller, et al.. (2022). Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers. 14(9). 2300–2300. 11 indexed citations

Ascierto, Paolo A., Brigitte Dréno, James Larkin, et al.. (2021). 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research. 27(19). 5225–5235. 119 indexed citations

Morris, Meg E., Natasha K. Brusco, Paul S. Myles, et al.. (2021). Protocol for implementation of the ‘AusPROM’ recommendations for elective surgery patients: a mixed-methods cohort study. BMJ Open. 11(9). e049937–e049937. 4 indexed citations

Dearden, Helen Clare, Lewis Au, Daniel Wang, et al.. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer. 153. 168–178. 24 indexed citations

10.

Atkinson, Victoria, Pietro Quaglino, Massimo Aglietta, et al.. (2021). A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers. 13(10). 2466–2466. 8 indexed citations

11.

Long, Georgina V., Caroline Robert, Marcus O. Butler, et al.. (2021). Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research. 27(19). 5280–5288. 24 indexed citations

12.

Hong, Angela, Brindha Shivalingam, Matteo S. Carlino, et al.. (2020). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. European Journal of Cancer. 142. 10–17. 18 indexed citations

13.

Ferrucci, Pier Francesco, Anna Maria Di Giacomo, Michele Del Vecchio, et al.. (2020). KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer. 8(2). e001806–e001806. 111 indexed citations

14.

Ascierto, Paolo A., Pier Francesco Ferrucci, Rosalie Fisher, et al.. (2019). Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine. 25(6). 941–946. 219 indexed citations

15.

Long, Georgina V., Axel Hauschild, Mario Santinami, et al.. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma. Annals of Oncology. 29. viii734–viii735. 13 indexed citations

16.

Hammerlindl, Heinz, Dinoop Ravindran Menon, Abdullah Al Emran, et al.. (2017). Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS -Mutant Cancers. Clinical Cancer Research. 24(5). 1090–1102. 15 indexed citations

17.

Tobin, Joshua W.D., Jane Royle, Robert M. Mason, et al.. (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. Blood. 130. 5338–5338. 4 indexed citations

18.

Atkinson, Victoria. (2017). Recent advances in malignant melanoma. Internal Medicine Journal. 47(10). 1114–1121. 32 indexed citations

19.

Ribas, Antoni, F. Stephen Hodi, Donald P. Lawrence, et al.. (2017). KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Annals of Oncology. 28. v430–v430. 26 indexed citations

20.

Atkinson, Victoria, Georgina V. Long, Alexander M. Menzies, et al.. (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation‐positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology. 12(S7). 5–12. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact